Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07118592 · ClinicalTrials.gov registry record · NA
Genetic Architecture of Natriuretic Peptides and Blood Pressure Response
A NA study, sponsored by University of Alabama at Birmingham.
- Not yet
- Registry status
- NA
- Development phase
- 200
- Enrollment target
NCT07118592 is a NA study that has not yet begun recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 200 participants.
The verdict
NCT07118592, a NA study, has not yet begun recruiting, sponsored by University of Alabama at Birmingham.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
Study Summary
Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.
Interventions
- DIETARY_SUPPLEMENT High Salt Diet
- DIETARY_SUPPLEMENT Low Salt Diet
- DIETARY_SUPPLEMENT Saline Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2030-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07118592
The ClinicalTrials.gov registry entry for NCT07118592 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which High Salt Diet is the first listed.
NCT07118592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07118592 about?
NCT07118592 is a clinical study titled "Genetic Architecture of Natriuretic Peptides and Blood Pressure Response". Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension...
What is the current status of trial NCT07118592?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2026-09-01. Estimated completion is 2030-12-01.
What interventions are being tested in trial NCT07118592?
The interventions under investigation include: High Salt Diet (DIETARY_SUPPLEMENT), Low Salt Diet (DIETARY_SUPPLEMENT), Saline Infusion (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07118592?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.